PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update

PRINCETON, N.J., March 27, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotechnology) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called Versamune today announced its financial results for the full year ended December 31, 2019 and provided a business update.